Biologic Specimen and Data Repository Information Coordinating Center
Home > Studies > SHEP

Resources Available

Study Datasets Only

Study Documents

PDF Data Dictionary (PDF - 2.0 MB)
PDF Definitions (PDF - 187.1 KB)
Forms (HTML )

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message.

If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

Systolic Hypertension in the Elderly Program (SHEP)

Clinical Trials URL: http://www.clinicaltrials.gov/ct/sh...
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on June 23, 2005
Study Dates: 1984-1996
Consent: Unrestricted Consent
Commercial Use Restrictions: No
NHLBI Division: DCVS
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information

Objectives

To assess the ability of antihypertensive drug treatment to reduce the risk of nonfatal and fatal (total) stroke in isolated systolic hypertension.

Background

Previous trials have demonstrated beneficial effects of antihypertensive treatment of diastolic hypertension on major morbidity and mortality, but none has investigated the ability to influence these events for persons with isolated systolic hypertension.

Subjects

4736 persons (1.06%) from 447,921 screenees aged 60 years and above were randomized (2365 to active treatment, 2371 to placebo). Systolic blood pressure ranged from 160 to 219 mm Hg and diastolic blood pressure was less than 90 mm Hg. Of the participants, 3161 were not receiving antihypertensive medication at initial contact, and 1575 were. The average systolic blood pressure was 170 mm Hg; average diastolic blood pressure, 77 mm Hg. The mean age was 72 years, 57% were women, and 14% were black.

Conclusions

In persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%, with 5-year absolute benefit of 30 events per 1000 participants. Major cardiovascular events were reduced, with 5-year absolute benefit of 55 events per 1000. (JAMA 1991; June 26:3255-64.).